Krsnaa Diagnostics Ltd (KRSNAA) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company demonstrated resilience in a seasonally soft quarter, with performance also impacted by conscious, temporary operational pauses in certain projects to accelerate the recovery of long-pending government receivables.
- A significant achievement during the quarter was the recovery of over INR 130 crores in receivables, materially strengthening the company's cash position and demonstrating improved working capital discipline.
- The B2C retail segment continued its strong growth trajectory, with revenue increasing 8 times year-on-year, contributing approximately 8% to the overall group revenue and acting as a second engine of growth.
- Margins were temporarily affected by cost absorption related to expansion initiatives, most notably the large-scale pathology rollout in Rajasthan, for which no revenue was recognized in Q3.
- The company achieved a strategic milestone with the launch of its first 'Apulki Healthcare' hospital in Pune, a PPP-based cancer and cardiac care facility, marking a calibrated extension into integrated tertiary care.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.